A 12-week Study to Compare the Efficacy and Safety of Albuterol Spiromax® Versus a Placebo in People 12 Years and Older With Persistent Asthma

Exclusion Criteria

• •Participation in any investigational drug trial within the 30 days preceding the Screening Visit (SV).
• •A known hypersensitivity to albuterol or any of the excipients in the formulations.
• •History of severe milk protein allergy.
• •History of a respiratory infection or disorder that has not resolved within the 2 weeks preceding the Screening Visit (SV).
• •Currently requires treatment with β2-adrenergic receptor antagonists or non-selective β-receptor blocking agents.
• •History of life-threatening asthma that is defined for this protocol as an asthma episode that required intubation.
• •Any asthma exacerbation requiring oral corticosteroids within 3 months of the Screening Visit (SV). A subject must not have had any hospitalization for asthma within 6 months prior to the Screening Visit (SV).
• •Historical or current evidence of any clinically significant non-asthmatic acute or chronic condition including.